A Study of Counseling Support for Cancer Survivors Age 65+
ConditionCancer Survivors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out if a psychotherapy method called brief behavioral activation (BBA) can improve depression, anxiety, and overall well-being and encourage healthy lifestyle behaviors in English- and Spanish-speaking Older Adult Cancer Survivors (OACS). BBA is a therapeutic technique that guides people to set goals and engage in enjoyable or rewarding activities as a way of changing behavior and reducing symptoms of depression. In this study, BBA will be given by telephone or videoconference (remotely).
Eligibility criteria
Qualifiers
As per self-report or medical record, ≥65 years old
As per self-report or medical record, has a history of cancer
currently with no evidence of disease (NED) AND/OR
6 months or more post-treatment
Disqualifiers
As per PI determination, requires a higher level of care for current passive or active suicidal ideation than current protocol is able to provide. If a participant receives a score of > 0 on item 9 of the PHQ-9, they will be referred to study PI for further evaluation using the Columbia-Suicide Severity Rating Scale (CSSR) (MSK Standard) to determine level of risk;. Only those with active suicidal ideation will be excluded and referred to a higher level of care.
As per self-report or as documented in the medical record, current untreated (e.g., no medication, no therapy) major psychotic disorder (schizotypal personality disorder, schizophreniform disorder, schizoaffective disorder). Patients diagnosed with a major psychiatric disorder will be reviewed by the study PI to determine eligibility prior to consent.
As per self-report or medical record, currently taking antidepressant medication for < 3 month
As per self-report, engagement in regular individual psychotherapeutic support that the participant is unable or unwilling to put on hold for the course of the study
Trial design
Treatments tested in this trial
- assessments (questionnaires)
Treatment groups
454 Participants
are divided into 2 treatment groupsSponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
National Institutes of Health (NIH)
Collaborator
Source ClinicalTrials.gov